Show simple item record

dc.contributor.authorElyashiv, O.
dc.contributor.authorLedermann, J.
dc.contributor.authorParmar, G.
dc.contributor.authorFarrelly, L.
dc.contributor.authorCounsell, N.
dc.contributor.authorFeeney, A.
dc.contributor.authorEl-Khouly, F.
dc.contributor.authorMacdonald, I.
dc.contributor.authorNeto, A.
dc.contributor.authorArthur-Darkwa, E.
dc.contributor.authorBurnett, E.
dc.contributor.authorJayson, Gordon C
dc.contributor.authorMileshkin, L.
dc.contributor.authorGourley, C.
dc.contributor.authorNicum, S.
dc.date.accessioned2020-12-08T05:36:38Z
dc.date.available2020-12-08T05:36:38Z
dc.date.issued2020en
dc.identifier.citationElyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, et al. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Int J Gynecol Cancer. 2020.en
dc.identifier.pmid33097567en
dc.identifier.doi10.1136/ijgc-2020-002073en
dc.identifier.urihttp://hdl.handle.net/10541/623535
dc.description.abstractBackground: Two novel biological agents-cediranib targeting angiogenesis, and olaparib targeting DNA repair processes-have individually led to an improvement in ovarian cancer control. The aim of ICON9 is to investigate the combination of cediranib and olaparib maintenance in recurrent ovarian cancer following platinum-based therapy. Primary objective: To assess the efficacy of maintenance treatment with olaparib in combination with cediranib compared with olaparib alone following a response to platinum-based chemotherapy in women with platinum-sensitive ovarian, fallopian tube or peritoneal cancer during first relapse. Study hypothesis: Maintenance therapy with cediranib and olaparib in combination is associated with improved patient outcomes compared with olaparib alone. Trial design: International phase III randomized controlled trial. Following a response to platinum-based chemotherapy patients are randomized 1:1 to either oral olaparib and cediranib (intervention arm) or oral olaparib alone (control arm). Major inclusion criteria: Patients with a known diagnosis of high grade serous or endometrioid carcinoma of the ovary, fallopian tube or peritoneum, progressing more than 6 months after first-line platinum-based chemotherapy, who have responded to second-line platinum-based chemotherapy. Primary endpoints: Progression-free and overall survival. Co-primary endpoints to be assessed using a fixed-sequence gatekeeping approach: (1) progression-free survival, all patients; (2) progression-free survival, BRCA wild type; (3) overall survival, all patients; (4) overall survival, BRCA wild type.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1136/ijgc-2020-002073en
dc.titleICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyen
dc.typeArticleen
dc.contributor.departmentUniversity College CRUK and UCL Cancer Trials Centre, UCL Cancer Institute, London, UKen
dc.identifier.journalInternational Journal of Gynecological Canceren
dc.description.noteen]
refterms.dateFOA2020-12-09T10:30:14Z


Files in this item

Thumbnail
Name:
33097567.pdf
Size:
383.7Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record